POMDOCTOR Ltd proposes ending its ADR program, directly listing Class A ordinary shares on Nasdaq, and consolidating shares 10-to-1 on the same date. The vote matters because investors must decide whether the company’s trading format and authorized share structure should change, with revised Class A, Class B and other share counts.

Key Highlights

  • POMDOCTOR would reduce authorized shares from 500,000,000 to 50,000,000 while keeping authorized Capital at US$50,000.
  • Shareholders of record on September 2, 2026, are eligible to vote at the September 30, 2026, meeting.
  • The board unanimously recommends approval of all proposed resolutions, including a possible adjournment for further proxy solicitation.

POMDOCTOR Ltd (NASDAQ: POM) is seeking Shareholder approval to end its American depositary receipt program and move its Class A ordinary shares to a direct Nasdaq listing on the same date. The proposed change is tied to a 10-to-1 share consolidation, making the meeting a vote on both the trading format and the company’s share structure.

Share Structure Would Shift to 50,000,000 Shares

The extraordinary general meeting will take place on September 30, 2026, in Guangzhou, People’s Republic of China. Holders recorded on September 2, 2026, will be entitled to attend and vote, while ADS holders may exercise voting rights through Citibank, N.A. under the deposit agreement. The consolidation would apply to issued and unissued capital. Every ten Class A ordinary shares and every ten Class B ordinary shares with a Par Value of US$0.0001 would become one share with a par value of US$0.001. Authorized capital would remain US$50,000 while changing from 500,000,000 shares to 50,000,000 shares. Class A shares would move from 450,000,000 to 45,000,000, Class B shares from 2,042,042 to 204,205, and other authorized shares from 47,957,958 to 4,795,795.

Board Supports All Proposed Resolutions

POMDOCTOR’s board unanimously recommends that shareholders vote for all proposals. The resolutions cover the ADR termination and direct listing, the share consolidation, and an adjournment if further proxy solicitation and voting are needed. The ADR termination, direct listing and share consolidation are intended to take effect simultaneously.